LASA vs WINDLAS: Stock Comparison

Lasa Supergenerics Limited vs Windlas Biotech Ltd

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Windlas Biotech Ltd is the larger company by market capitalisation. Windlas Biotech Ltd shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Lasa Supergenerics Limited and Windlas Biotech Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, LASA is more favourable on 1 of 11 scored metrics and WINDLAS on 10These counts are context-free and are not an overall rating.

Key Differences

Market Cap
WINDLAS is the larger company
₹1,754 Cr vs ₹35 Cr
EPS
WINDLAS has higher earnings per share
₹31.5 vs ₹-6.8
Dividend Yield
WINDLAS has a higher dividend yield
0.73% vs 0%
Revenue Growth (TTM YoY)
WINDLAS has faster revenue growth
17.7% vs 0%
EPS Growth (TTM YoY)
LASA has faster EPS growth
0% vs -2.6%
Qtr Sales Growth
WINDLAS has stronger quarterly sales growth
17.7% vs -100%
Qtr Profit Growth
WINDLAS has stronger quarterly profit growth
-1.78% vs -139%
ROE
WINDLAS has a higher ROE
12.2% vs -19.6%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricLASAWINDLAS
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricLASAWINDLAS
Live Price₹6.86₹849
Day Change0.59%-0.99%
Volume9,68513,436
52-Week High₹14.08₹1,097.9
52-Week Low₹5.67₹697.4
Distance from 52W High-51.28%-22.67%

Valuation

MetricLASAWINDLAS
Market Cap₹35 Cr₹1,754 Cr
P/E Ratio26.93x
P/B Ratio3.08x
EPS₹-6.8₹31.5
Book Value₹9.89₹275
Dividend Yield0%0.73%

Growth

MetricLASAWINDLAS
Revenue Growth (TTM YoY)0%17.7%
EPS Growth (TTM YoY)0%-2.6%
Qtr Sales Growth-100%17.7%
Qtr Profit Growth-139%-1.78%

Profitability & Leverage

MetricLASAWINDLAS
ROE-19.6%12.2%
ROCE-18.2%15.9%
Net Margin-135.6%7.35%
Operating Margin-29.3%11.6%
Debt to Equity0.2x0.06x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricLASAWINDLAS
Promoter Holding53.65%63.31% 1.41 pp
FII Holding0%2.04% 1.44 pp
DII Holding0%9.84% 1.97 pp
Public Holding46.35%24.8% 0.9 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Lasa Supergenerics Limited and Windlas Biotech Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.